Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CentoRx update

CNTO provided a clinical progress update in its quarterly conference call.

The 1,400-patient European Capture trial of CentoRx gpIIb/IIIa inhibitor for unstable angina, renamed ReoPro, is

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE